

## List of Study Group 2016-2017

\*\*\*2017\*\*\*

1. Ishiguro A, Ezinne CC, Michihata N, Nakadate H, Manabe A, Taki M, et al. Pediatric thromboembolism: a national survey in Japan. *Int. J. Hematol.* 2017; 105: 52-8.
2. Miyamoto T, Takashima S, Kato K, Takase K, Yoshimoto G, Yoshida S, et al. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation. *Int. J. Hematol.* 2017; 105: 92-9.
3. Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, et al. Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation. *Int. J. Hematol.* 2017; 105: 369-76.
4. Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, et al. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. *Int. J. Hematol.* 2017; 105:309-17.
5. Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, et al. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials. *Int. J. Hematol.* 2017; 105:485-96.
6. Takahashi N, Nakaseko C, Kobayashi K, Miyamura K, Ono C, Koide Y, et al. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. *Int. J. Hematol.* 2017; 106:398-410.

7. Kawabata H, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, et al.. Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. *Int. J. Hematol.* 2017; 106:375-84.
8. Saito A, Isoda A, Kojima M, Yokohama A, Tsukune Y, Sasaki M, et al. Retrospective analysis of prognostic factors for Waldenström macroglobulinemia: a multicenter cooperative study in Japan. *Int. J. Hematol.* 2017; 106:in press, 10.1007/s12185-017-2297-y.
9. Maruyama D, Tobinai K, Ogura M, Uchida T, Hatake K, Taniwaki K, et al.. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. *Int. J. Hematol.* 2017; 106:in press, 10.1007/s12185-017-2286-1
10. Miyagi Maeshima A. Distribution of malignant lymphomas in the anterior mediastinum: A single-institution study of 76 cases in Japan, 1997-2016. *Int. J. Hematol.* 2017; 106:in press
11. Takahashi N. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic-phase chronic myeloid leukemia: The JALSG-STIM213 Study. . *Int. J. Hematol.* 2017; 106:in press

\*\*\*2016\*\*\*

1. Rika S, Masataka T, Kumi O, Takehiko M, Hiroatsu A, Souichi A, et al. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. *Int. J. Hematol.* 2016; 103:322-33.

2. Keino D, Kinoshita A, Tomizawa D, Takahashi H, Ida K, Kurosawa, H, et al. Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group. *Int. J. Hematol.* 2016; 103:416-22.
3. Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. *Int. J. Hematol.* 2016; 103:686-92.
4. Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. *Int. J. Hematol.* 2016; 104: 99-109.
5. Koh K, Ogawa C, Okamoto Y, Kudo K, Inagaki J, Morimoto T, et al. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan. *Int. J. Hematol.* 2016; 104:245-55.